ReviewCurrent atherosclerosis reports2022
Remnants, LDL, and the Quantification of Lipoprotein-Associated Risk in Atherosclerotic Cardiovascular Disease.
Review in Current atherosclerosis reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 45 citations in OpenAlex.
- Remnant cholesterol inflammation index (RCII) as a potential biomarker for ACPA-negative rheumatoid arthritis: evidence from dual-cohort analysis and serum lipidomics.Clinical rheumatology · 2026Article
- Inflammation in atherosclerosis: Drivers, mechanisms and therapies.Acta pharmaceutica Sinica. B · 2026Review
- Association between remnant cholesterol and colorectal cancer risk in Korea: a nationwide population-based study.The Korean journal of internal medicine · 2026Article
- A Narrative Review of Remnant Cholesterol as an Independent Atherogenic Lipoprotein in Type 2 Diabetes: Pathophysiology and Clinical Implications.Therapeutics and clinical risk management · 2026Review
- Correlation Between Apolipoprotein B and Severity of Coronary Artery Stenosis in Individuals Aged 45 and Above: A Cross-Sectional Study.Cardiovascular therapeutics · 2026Article
- Small dense LDL: An underestimated driver of atherosclerosis (Review).Molecular medicine reports · 2025Review
- Article
- Triglycerides, Triglyceride-Rich Lipoproteins, and Remnant Cholesterol in Atherosclerotic Cardiovascular Disease.Journal of lipid and atherosclerosis · 2025Review
- Daily steps, cardiorespiratory fitness, and remnant cholesterol in schoolchildren: mediation effects for cardiovascular prevention.Pediatric research · 2025Article
- Beyond LDL cholesterol: remnant cholesterol is associated with cardiometabolic risk factors in children.BMC medicine · 2025Article
- Non-traditional lipid biomarkers in atherosclerotic cardiovascular disease: pathophysiological mechanisms and strategies to address residual risk.Frontiers in endocrinology · 2025Review
- Impact of Remnant Cholesterol on Cardiovascular Risk in Diabetes.Current diabetes reports · 2024Review
- It is time to address the contribution of cholesterol in all apoB-containing lipoproteins to atherosclerotic cardiovascular disease.European heart journal open · 2024Review
- Relationship between remnant cholesterol and short-term prognosis in acute ischemic stroke patients.Brain and behavior · 2024Article
- Higher remnant cholesterol is associated with an increased risk of amnestic mild cognitive impairment: a community-based cross-sectional study.Frontiers in aging neuroscience · 2024Article
- Triglyceride-rich lipoproteins and cardiovascular diseases.Frontiers in endocrinology · 2024Review
- How to Handle Elevated Triglycerides: Life after PROMINENT.Current atherosclerosis reports · 2023Review
- Triglyceride-Rich Lipoproteins and Remnant Cholesterol in Cardiovascular Disease.Journal of Korean medical science · 2023Review
- Management of Obesity-Related Inflammatory and Cardiovascular Diseases by Medicinal Plants: From Traditional Uses to Therapeutic Targets.Biomedicines · 2023Review
- Serum LDL-C/HDL-C ratio and the risk of carotid plaques: a longitudinal study.BMC cardiovascular disorders · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewImplementation of intensive LDL cholesterol (LDL-C) lowering strategies and recognition of the role of triglyceride-rich lipoproteins (TRL) in atherosclerosis has prompted re-evaluation of the suitability of current lipid profile measurements for future clinical practice. RECENT
findingsAt low concentrations of LDL-C (< 1.8 mmol/l/70 mg/dl), the Friedewald equation yields estimates with substantial negative bias. New equations provide a more accurate means of calculating LDL-C. Recent reports indicate that the increase in risk per unit increment in TRL/remnant cholesterol may be greater than that of LDL-C. Hence, specific measurement of TRL/remnant cholesterol may be of importance in determining risk. Non-HDL cholesterol and plasma apolipoprotein B have been shown in discordancy analyses to identify individuals at high risk even when LDL-C is low. There is a need to adopt updated methods for determining LDL-C and to develop better biomarkers that more accurately reflect the abundance of TRL remnant particles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.